DeciBio

We are pleased to announce the speakers for our upcoming webinar, Emerging Applications and Platforms in Liquid Biopsy, on Wednesday, November 6, 2024. Join us for this discussion led by: Rehan Verjee, Chief Executive Officer, Precede Biosciences Dawn Mattoon, Chief Executive Officer, Mercy BioAnalytics, Inc. Peter B., Chief Medical Officer, DELFI Diagnostics Sarah Clancey Overton, Director of RCM, Velsera Mark Sausen, Executive Director, Head of Technology Innovation, PGDx, Labcorp Together, our distinguished speakers will explore advancements in liquid biopsy, including innovations in early cancer detection, epigenomics, and targeted therapies, while addressing challenges in access and reimbursement. Webinar Details 📅 Date: Wednesday, November 6, 2024 ⏰ Time: 9:00 AM - 10:00 AM PST 🔗Register here: https://lnkd.in/gKZBQanP #precisionmedicine #liquidbiopsy

We’re sending out a contingent to San Francisco for the 2025 JPM Healthcare Week! From January 12-16, our team of partners, project leaders, and industry experts will be ready to discuss the evolving precision medicine market– spanning next generation sequencing, spatial biology, infectious disease, bioinformatics, digital pathology, radiomics, early cancer detection, liquid biopsy, advanced therapies, and women’s health. If you're attending, let’s connect and explore how our insights and strategies can help drive your next commercial launch. #JPM2025 #PrecisionMedicine

Ah, can’t believe the New Year is just around the corner and that this event is just next month! I'm looking forward to moderating the PDA West Coast Chapter (PDA WCC) 10th Annual Women in Life Sciences Panel next month at Genentech in South San Francisco on January 30, 2025. This event's theme focuses on Empowerment, creating an environment where women feel confident, supported, and equipped to thrive. It’s always inspiring to hear stories and insights from women leaders who’ve navigated the unique challenges of our industry. I’m especially excited to help foster discussions that invite both men and women to join the conversation about uplifting and empowering women in life sciences. Early bird tickets are available until December 20! Hope to see you there: https://lnkd.in/g9SW5CEY Also if you're in the Bay, that following Sunday Feb 2 - I'll be riding with Cycle for Survival at the Palo Alto Equinox. Ping me if you'd like to join and support rare cancer research!

Meet David Cavanaugh! David Cavanaugh is the co-founder of DeciBio Consulting, where he actively engages in the firm’s consulting, data, and venture capital activities. With a strong passion for advancing precision medicine, he is particularly excited about extending its applications beyond oncology into other therapeutic areas. In his free time, David enjoys running, exploring new cultures through international travel, indulging in diverse cuisines, and cherishing moments with his husband and their chiweenie, Didier! Meet with David at the upcoming JPM Conference, from January 13-16 in San Fransisco, CA. Learn more about our DxBooks here: https://lnkd.in/gX66v7HD Want to be a part of our team? Check out our open positions or learn more about us on our website: https://lnkd.in/gteq7n_F #meettheteam #precisionmedicine

Thankful for the #LBx news last month. November brought several funding rounds, litigation updates, and new guidance from FDA.     Clinical and Regulatory: The FDA approved FoundationOne Liquid CDx to be used as a companion diagnostic for tepotinib, intended for adult patients with metastatic NSCLC with MET exon 14 skipping alterations. The FDA also released a guidance document providing non-binding recommendations around ctDNA use in clinical trials for early-stage solid tumors, focusing on industry and drug development settings and especially highlighting considerations around MRD / monitoring applications. While the guidance does not recommend specific assays, it provides a list of different potential applications of ctDNA and different considerations for them. The guidance also suggests approaches for validation, recommending clinical specimens for confirming assay limit of detection or developing an appropriate set of reference materials to allow for comparability across multiple MRD assays.    Company Announcements & Product Launches: Breakthrough Genomics announced a collaboration with the PRECEDE Consortium Study to advance the clinical evaluation and adoption of its BT-Reveal Early Pancreatic Cancer Test. The partnership offers Breakthrough Genomics access to a network of pancreatic cancer researchers, clinicians, and high-risk centers.    M&A | VC | Private Equity | Legal: A jury awarded Guardant Health $292.5M in damages related to a false-advertising and unfair-competition lawsuit brought against Natera in 2021. The claims were not about Signatera’s performance but alleged misleading advertisements around the performance of the competing Guardant Reveal assay.  PrognomiQ Inc announced $34M Series D financing, which will be used to advance development of an early detection test for lung cancer. In response to QIAGEN’s patent infringement lawsuit, Zymo Research Corp filed counterclaims of antitrust violations and interference, accusing Qiagen of using legal tactics to stifle innovation and hinder adoption of Zymo’s ‘breakthrough cfDNA technology’. OneCell Diagnostics Inc. also raised $16M in Series A funding, which will be used to expand its next-generation liquid biopsy test, OncoIndx Ikon to the U.S. market.    Read the newsletter for more: https://lnkd.in/gY_sq6KK   Sign up to receive our Liquid Biopsy Newsletter in your email: https://lnkd.in/gKQn7_zp   The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad   #newsletter #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting 

Check out our November AI newsletter! We have several updates: AI in Drug Discovery - Cradle, whose AI-powered protein engineering platform aims to accelerate R&D, has raised $73 million. Nabla Bio has released new preclinical results in AI-driven antibody design. Formation Bio, OpenAI, and Sanofi have released Muse, an AI-powered tool designed to address key inefficiencies in trial enrollment. The Arc Institute and Stanford University have made progress in the field of synthetic biology with Evo, an AI biology model that may help streamline gene editing. AI in Diagnostics - Institut Curie in France has integrated Ibex Medical Analytics’ AI-powered diagnostic tools into routine clinical practice. Researchers at Mass General Brigham have developed an AI algorithm to identify long COVID cases from electronic health records with greater accuracy and inclusivity. Philips and icometrix have unveiled an integrated AI solution to enhance MRI-based diagnosis and treatment monitoring for neurological conditions. Annalise.ai’s AI-powered chest X-ray decision-support system is being implemented by seven NHS Trusts in diseases such as lung cancer. AI in Healthcare - Mount Sinai Health System has launched the Hamilton and Amabel James Center for Artificial Intelligence and Human Health. Citizen Health a comprehensive health and AI-driven company with a focus on rare disease, has secured $14.5 million in seed funding. RESEARCH GRID has secured $6.5 million in seed funding to address inefficiencies in clinical trials. Finally, health policy staffers and industry leaders convened at the Capitol for a Coalition for Health AI event to discuss bipartisan efforts in artificial intelligence policy. Check out the newsletter to learn more about these updates in AI and Machine Learning: https://lnkd.in/gmq8pHqt Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These headlines were curated by Luka Jelcic, Merouane Ounadjela, Eliza French, Katie Schneider, Graham F., and Rebecca Bair. #AI #Healthcare #Diagnostics #DrugDiscovery

November Highlights  November 2024 gave us more digital health news! Read about it here:   Disease Management / Digital Therapeutics  Dexcom has invested in ŌURA to enable integration of Dexcom glucose monitoring with Oura’s health tracking ring, set to launch in 2025 for personalized health insights. Naitive and Parvizi Surgical Innovation are partnering to advance OsteoSight, a tool for detecting osteoporosis via routine X-rays, aiming for early diagnosis and treatment within clinical settings.   Informatics / Healthcare IT Solutions  Rula’s mental health care network will join Amazon Health Services, providing patients with tailored access to mental health providers nationwide. Practice Better received $13 million in funding to develop its health solution software with AI-driven feature integration and additional developments.   Women’s Health / Femtech  OncoGenomX is collaborating with the VA to test its PredictionStar platform, which aims to personalize breast cancer treatment using genomic and proteomic data. Alife’s Embryo Assist software is being piloted through US Fertility to streamline IVF lab operations and enhance transparency and efficiency for patients. Check out the newsletter to learn more about these updates in digital health and informatics: https://lnkd.in/gFHdpUQz Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These headlines were curated by Katie Schneider, Katherine Erickson, and Emily L..   #DigitalHealth #Informatics #Healthcare #Diagnostics #FemTech 

Katie Maloney, Partner and head of our London office, will be attending the Digital Pathology & AI Congress in London next week! As we approach the holidays and wrap up the year, this is a great chance to connect with industry leaders and reflect on how digital pathology and AI are transforming diagnostics. If you're attending, don't miss the opportunity to catch up with Katie and explore what’s ahead for 2025. We are looking forward to seeing many of you there! If you're interested in connecting with our team to discuss our Digital & Computational Pathology Market Report, feel free to reach out on LinkedIn or email Katie at [email protected]. #DigitalPathology #AIinHealthcare #PrecisionMedicine

Fresh from Thanksgiving, we’re feeling especially grateful for what makes DeciBio truly special—our people. As we wrap up the year, we’re reminded that investing in our team has always been our best strategy for growth. One way we do that? Our offsites. Read our latest blog, "Investing in People: Why DeciBio's Offsites Are Our Secret Weapon," to see how these events amplify our core values and drive ROI for our team and business: https://lnkd.in/gaPgrsF7 #CompanyOffsite #TeamBonding #InvestingInPeople #TeamCulture

It’s #GivingTuesday, and Cycle for Survival is matching online donations today only! DeciBio is proud to participate in this incredible initiative, with teams from all our global offices joining forces to support rare cancer research at Memorial Sloan Kettering Cancer Center. Rare cancers account for about half of all cancer diagnoses, yet research in this area is significantly underfunded. Since 2007, funds raised through Cycle for Survival have enabled transformative advancements in how rare cancers are diagnosed and treated, including making tumor sequencing a standard of care for every solid tumor patient at Memorial Sloan Kettering Cancer Center. This year, our team captains Megan Nacar, Hannah Glazier, Miguel Edwards, Ph.D., Samuel P., and Katie Maloney are leading the charge from Los Angeles, Boston, Palo Alto, New York City, and even remotely from London! Join us in making a difference. Donate today to take advantage of matched donations—gifts up to $5,000 are matched dollar for dollar, and contributions of $5,000 or more are double-matched! Share your support donating or by commenting below with the team or city you’re cheering for or would like to ride with! At DeciBio, our mission is to accelerate innovation in precision medicine, and a fulfilling part of that mission is seeing these innovations impact lives. Together, let’s fund breakthroughs for patients who need them the most. Donate here for our HQ Team: https://lnkd.in/gm4RBbbc #GivingTuesday #BeatRareCancers #CycleforSurvival